Jideytro

(Zidesamtinib (NVL-520))

Phase 2Small molecule

NNuvalent Inc.

Jideytro is one of 13 small molecule programs targeting Other Solid Tumors. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Patents

Pipeline

Status by Indication[3][1]

Indication

Other Solid TumorsRecruiting

Other Solid TumorsPhase 2

Recruiting

Competition

Competitive Landscape

12 competitors in Other Solid Tumors

#DrugCompanyPhaseTrials

Beyfortus

BeiGene

Phase 2

2 2

Erbitux

IImclone

Phase 2

1 3

Gemzar

Johnson & Johnson

Phase 1

2 4

Adriamycin

Pfizer

Phase 1

1 5

JAB 21822

AAllist Pharmaceuticals, Inc.

Phase 2

1 6

Velcade

SShilpa Grover, MD, MPH

Phase 1

2 7

Tuoyi

CCoherus Oncology, Inc.

Phase 1

1 8

MCLA-129

BBetta Pharmaceuticals Co., Ltd.

Phase 2

1 9

Jideytro

NNuvalent Inc.

Phase 2

1 10

BL-B01D1

SSichuan Baili Pharmaceutical Co., Ltd.

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 1/2Recruiting

Other Solid Tumors

NCT05118789

Clinical

Trials by Indication[1]

Other Solid Tumors1 trial

A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)

Recruiting·NNuvalent Inc.·Phase 1/2·NCT05118789·359 enrolled

Regulatory

FDA Approval Timeline[4]

Jul 21, 2026

JIDEYTRO

NDA NDA220185

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Zidesamtinib (NVL-520). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Zidesamtinib (NVL-520) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Zidesamtinib (NVL-520). EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA220185). U.S. Food & Drug Administration.
[5]
FDA Orange Book — Patent and exclusivity data for Jideytro. U.S. Food & Drug Administration.
[6]
SEC EDGAR — Nuvalent Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: NNuvalent Inc.

Patent Landscape[5]

Patent Cliff

May 4, 2041

Earliest patent expiration — generic entry possible after this date

Patent #Expires

12054498May 4, 2041

11542278May 4, 2041

12630560Sep 29, 2042

12043626Sep 29, 2042

Jideytro

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Other Solid Tumors1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Patent Landscape[5]

Related News